#4724
Expert Nurse
Kathleen Madden

We too have been following approval indications, and have been fielding questions from patients. This patient population we have typically been promoting clinical trial options, typically adjuvant vaccines, however some of the adjuvant ICI trials are starting to expanding to include early stage III patients.

On another note, I know that serum marker research is well into development but not ready for release yet. My hope is that advancement with lab markers will assist in evaluating risk for recurrence and help with questions such as this in weighing risks / benefits and lead to other immunologic tests evaluating potentential for irAE’s for all pts but especially early stage adjuvant patients.